We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
+12.46%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$670M
AUM Growth
+$172M
Cap. Flow
+$46.7M
Cap. Flow %
6.97%
Top 10 Hldgs %
63.01%
Holding
164
New
62
Increased
39
Reduced
20
Closed
34

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$6.49M
2
CNVS icon
Cineverse
CNVS
+$6.05M
3
SHIP icon
Seanergy Maritime Holdings
SHIP
+$5.68M
4
RMTI icon
Rockwell Medical
RMTI
+$5.66M
5
SRNE
Sorrento Therapeutics, Inc.
SRNE
+$5.55M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$16.6M
2
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$10.7M
3
XERS icon
Xeris Biopharma Holdings
XERS
+$2.89M
4
PLLL
Piedmont Lithium Limited American Depositary Receipts
PLLL
+$2.88M
5
ALNA
Allena Pharmaceuticals
ALNA
+$2.42M

Sector Composition

Rank Sector Weight
1 Miscellaneous 84.35%
2 Healthcare 13.68%
3 Technology 0.73%
4 Industrials 0.61%
5 Communication Services 0.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BKYI
126
BIO-key International
BKYI
$3.84M
$44K 0.01%
+69
New +$65.2K
ASXC
127
PUT
DELISTED
Asensus Surgical, Inc.
ASXC
$28K ﹤0.01%
794
– –
LPCN icon
128
PUT
Lipocine
LPCN
$18.1M
$21K ﹤0.01%
9
+3
+50% +$80
TEUM
129
PUT
DELISTED
Pareteum Corporation
TEUM
$20K ﹤0.01%
299
+109
+57% +$73
ALT icon
130
CALL
Altimmune
ALT
$628M
– –
-189
Closed -$202K
ATNM icon
131
Actinium Pharmaceuticals
ATNM
$39.3M
– –
-32,410
Closed -$357K
CLDX icon
132
Celldex Therapeutics
CLDX
$3.02B
– –
-73,094
Closed -$856K
DOMH icon
133
Dominari Holdings
DOMH
$53.1M
– –
-20,125
Closed -$281K
ENLV icon
134
Enlivex Ltd
ENLV
$15.4M
– –
-862
Closed -$65K
GLBS icon
135
Globus Maritime Ltd
GLBS
$77.7M
– –
-47,767
Closed -$1.27M
GLD icon
136
PUT
SPDR Gold Trust
GLD
$145B
– –
-215
Closed -$3.6M
GNPX icon
137
Genprex
GNPX
$2.71M
– –
-3
Closed -$372K
RKTO
138
Rocket One Inc
RKTO
$18.4M
– –
-2,747
Closed -$177K
IMNN icon
139
CALL
Imunon
IMNN
$7.86M
– –
-3
Closed -$243K
IMNN icon
140
PUT
Imunon
IMNN
$7.86M
– –
-1
Closed -$54K
IMUX icon
141
Immunic
IMUX
$141M
– –
-5,301
Closed -$642K
INO icon
142
CALL
Inovio Pharmaceuticals
INO
$120M
– –
-208
Closed -$6.72M
MBIO icon
143
Mustang Bio
MBIO
$3.82M
– –
-313
Closed -$747K
ORMP icon
144
PUT
Oramed Pharmaceuticals
ORMP
$192M
– –
-949
Closed -$335K
AGPU
145
Axe Compute Inc
AGPU
$128M
– –
-745
Closed -$367K
XBI icon
146
State Street SPDR S&P Biotech ETF
XBI
$10.4B
– –
-2,150
Closed -$241K
XERS icon
147
Xeris Biopharma Holdings
XERS
$1.37B
– –
-1,086,031
Closed -$2.89M
YTRA icon
148
Yatra Online
YTRA
$64.6M
– –
-650,000
Closed -$441K
LFWD icon
149
ReWalk Robotics
LFWD
$20M
– –
-227
Closed -$34K
NKLA
150
PUT
DELISTED
Nikola Corporation Common Stock
NKLA
– –
-12
Closed -$2.33M
3 4 5
6
7

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q3 2020 Portfolio in Review

As of Q3 2020, Sabby Management held 164 positions worth $670M, up 34% from $498M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Sabby Management deployed $46.7M of net new capital in Q3 2020, opening 62 new positions and adding to 39 existing holdings. Its largest new stake was Cineverse: 243,797 shares worth $2.75M.

By sector, the portfolio is most concentrated in Miscellaneous at 84% of assets, down from 87% a quarter earlier, followed by Healthcare and Technology.

On the sell side, the largest reduction was Biogen, an estimated $16.6M trimmed.

  • Sabby Management's largest Q3 2020 buy was Cineverse: 243,797 shares worth $2.75M.
  • Sabby Management added most to AstraZeneca in Q3 2020, an estimated $6.49M increase.
  • Sabby Management's biggest Q3 2020 reduction was Biogen, cutting an estimated $16.6M.
  • Sabby Management fully exited Xeris Biopharma Holdings in Q3 2020, selling an estimated $2.89M.
  • Sabby Management's ten largest holdings make up 63% of its $670M portfolio in Q3 2020.
  • Sabby Management opened 62 new positions and closed 34 in Q3 2020.
  • Sabby Management's portfolio value rose 34% quarter-over-quarter to $670M.

Based on Sabby Management's 13F filing for Q3 2020, filed 16 Nov 2020.